



A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma

13/08/2025 23:40:01

Main Information

Primary registry identifying number

LBCTR2020074518

Protocol number

OPERA2020

MOH registration number

Study registered at the country of origin

Yes

Study registered at the country of origin: Specify

Type of registration

Prospective

Type of registration: Justify

N/A

Date of registration in national regulatory agency

10/07/2020

Primary sponsor

General Research Grant

Primary sponsor: Country of origin

United Arab Emirates

Date of registration in primary registry

11/11/2021

Date of registration in national regulatory agency

10/07/2020

Public title

A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma

Acronym

OPERA

Scientific title

A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma

Acronym

OPERA

Brief summary of the study: English



Background and objective: Renal cell carcinoma (RCC), the eighth most common malignancy affecting adults, accounts for around 4% of new cancer cases in the United States. It is the seventh most common cancer in men and the ninth most common in women. The targeted therapies with Tyrosine Kinase inhibitors (TKI) and immune-based treatments are important components of treatment for advanced kidney cancer. This study will be conducted to describe the pattern of use of TKI and/or immunotherapy treatment options whether as monotherapy or in combination regimen and to assess the potency of the therapy sequence in routine clinical practice.

Methods: This is a regional, multicenter observational prospective study, to gather routine clinical practice data on the usage patterns and outcomes of immunotherapy and/or TKI, for metastatic RCC. One hundred eighty-five patients diagnosed with metastatic renal cell carcinoma and will be on immunotherapy and/or TKI in this observational study will be enrolled over three years.

Assessment: Efficacy parameters include response to treatment, duration of progression-free survival, duration of overall survival, partial response, time to response, Karnofski Performance Status, and tumor assessment. Safety parameters will include laboratory data, ECG, adverse events, and serious adverse events as pruritus, diarrhea, and organ toxicity as liver, lungs, kidneys, thyroid, and neurologic. Data will be recorded at different at baseline, during treatment at 3, 6, 12, and 36 months, and at every follow-up once yearly after the last administration of immunotherapy and TKI until the last follow-up.

Brief summary of the study: Arabic

% من حالاته 4 أنه ثامن أكثر الأورام الخبيثة شيوعاً التي تصيب البالغين ، يمثل حوالي : (RCC) الخلفية والهدف: سرطان الخلايا الكلوية السرطان الجديدة في الولايات المتحدة. وهو سابع أكثر أنواع السرطان شيوعاً بين الرجال والتاسع الأكثر شيوعاً بين النساء. تعد العلاجات والعلاجات القائمة على المناعة مكونات مهمة لعلاج سرطان الكلى المتقدم. سيتم إجراء هذه (TKI) المستهدفة باستخدام مثبطات التيروزين كيناز و / أو خيارات العلاج المناعي سواء كعلاج وحيد أو في نظام مشترك لتقييم فعالية تسلسل العلاج في TKI الدراسة لوصف نمط استخدام الممارسة السريرية الروتينية الطرق: هذه دراسة استطلاعية رصدية إقليمية متعددة المراكز لجمع بيانات الممارسة السريرية الروتينية حول أنماط ونتائج استخدام العلاج لـ سرطان الخلايا الكلوية المنتشر. مائة وخمسة وثمانون مريضاً تم تشخيصهم بسرطان الخلايا الكلوية المنتشر وبخضوعهم لـ TKI المناعي و / أو في هذه الدراسة المستقبلية سيتم تسجيلهم على مدى ثلاث سنوات TKI للعلاج المناعي و / أو التقييم: تشمل معلمات الفعالية الاستجابة للعلاج ، ومدة البقاء على قيد الحياة الخالية من التقدم ، ومدة البقاء الكلي ، والاستجابة الجزئية ، ووقت تقييم الورم. تشمل معايير الأمان بيانات المختبر ، وتخطيط القلب ، والأحداث السلبية ، والأحداث السلبية ، Karnofski ، وحالة أداء الخطيرة مثل الحكة ، والإسهال ، وتسمم الأعضاء مثل الكبد والزنك والكلى والغدة الدرقية والعصبية. سيتم تسجيل البيانات بشكل مختلف عند حتى آخر TKI شهرًا ، وفي كل متابعة مرة واحدة سنوياً بعد آخر إدارة للعلاج المناعي و 36 و 12 و 6 و 3 خط الأساس ، وأثناء العلاج في متابعة.

Health conditions/problem studied: Specify

Patients with:

- histologically confirmed metastatic renal cell cancer
- treated by immunotherapy and/or TKI

Interventions: Specify

Any immunotherapy and TKI prescribed for the management of mRCC as per FDA/EMA approval

Key inclusion and exclusion criteria: Inclusion criteria

- Patients ≥ 18 years old
- Histologically confirmed metastatic renal cell cancer
- Patients treated by immunotherapy and/or TKI
- Signed informed consent form obtained prior to study entry only for living patients

Key inclusion and exclusion criteria: Gender

Both

Key inclusion and exclusion criteria: Specify gender

Key inclusion and exclusion criteria: Age minimum

18

Key inclusion and exclusion criteria: Age maximum

80

Key inclusion and exclusion criteria: Exclusion criteria

- History of another malignancy within the past 5 years except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
- Pregnancy
- Current participation in another clinical trial

Type of study

Observational

Type of intervention

N/A

Type of intervention: Specify type

N/A

Trial scope

N/A

Trial scope: Specify scope

N/A

Study design: Allocation

N/A

Study design: Masking

N/A

Study design: Control

N/A

Study phase

N/A

Study design: Purpose

N/A

Study design: Specify purpose

N/A

Study design: Assignment

N/A

Study design: Specify assignment

N/A

IMP has market authorization
IMP has market authorization: Specify
Name of IMP
Year of authorization
Month of authorization
Type of IMP
Pharmaceutical class
Therapeutic indication
Therapeutic benefit
Study model

Case-Only

Study model: Explain model

Pure observational study

Study model: Specify model

N/A

Time perspective

Prospective

Time perspective: Explain time perspective

-First Patient in: 01 July 2021
-Last Patient in: 01 January 2024
-Last Patient out: 01 January 2025
-Estimated enrolment duration: 2.5 years
-Estimated follow-up duration: Until death, loss to follow-up or study termination.
-Database lock planned date: 30 March 2025

Time perspective: Specify perspective

N/A

Target follow-up duration
Target follow-up duration: Unit

12	months
Number of groups/cohorts	
4	
Biospecimen retention	Biospecimen description
Samples without DNA	Metastatic Cell Carcinoma
Target sample size	Actual enrollment target size
185	
Date of first enrollment: Type	Date of first enrollment: Date
Anticipated	01/07/2021
Date of study closure: Type	Date of study closure: Date
Anticipated	01/01/2025
Recruitment status	Recruitment status: Specify
Recruiting	
Date of completion	
30/03/2025	
IPD sharing statement plan	IPD sharing statement description
No	Summary Results Reporting
Additional data URL	
Admin comments	
Trial status	
Approved	

Secondary Identifying Numbers	
Full name of issuing authority	Secondary identifying number
NA	NA



Sources of Monetary or Material Support

Name

NA

Secondary Sponsors

Name

NA

Contact for Public/Scientific Queries

Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Marwan Ghosn	Hotel Dieu	Lebanon	01613395	marwan.ghosn@usj.edu.lb	Principle Investigator
Scientific	Marwan Ghosn	Hotel Dieu	Lebanon	01613395	marwan.ghosn@usj.edu.lb	Principle Investigator

Centers/Hospitals Involved in the Study

Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Hotel Dieu de France, Beirut	Prof. Marwan Ghosn	Oncology/ Hematology	Approved
Hammoud Hospital University Medical Center, Saida	Prof. Fadi Farhat	Oncology/ Hematology	NA
Sheikh Khalifa Specialty Hospital (SKSH)-Ras al Khaimah	Dr. Hassan Jaafar	Oncology/ Hematology	NA
King Faisal Specialty Hospital- Jeddah	Prof. Jamal Zekri	Medical Oncology	NA
King Saud bin Abdul Aziz -Jeddah	Prof. Mubarak Mansour	Medical Oncology	NA
Kuwait Cancer Control Center	Dr. Ehab Abdou	Medical Oncology	NA
King Hussein Cancer Center - KHCC	Dr. Samer Salah	Medical Oncology	NA
Cairo University Hospitals	Prof. Emad Hamada	Medical Oncology	NA
Kasr Al Aini Hospital	Prof. Hamdy Abdel Azim	Medical Oncology	NA



Ethics Review

Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Hotel Dieu de France	30/06/2020	Nancy Alam	nancy.alam@usj.edu.lb	01421229
Hotel Dieu de France	31/05/2021	Nancy Alam	nancy.alam@usj.edu.lb	01421229

Countries of Recruitment

Name
Lebanon
Saudi Arabia
United Arab Emirates
Egypt
Kuwait
Jordan

Health Conditions or Problems Studied

Condition	Code	Keyword
renal cell carcinoma	Carcinoma in situ of other specified sites (D09.7)	renal cell carcinoma

Interventions

Intervention	Description	Keyword
Immunotherapy and/or TKI	This is a regional, multicenter observational prospective study, to obtain routine clinical practice data on the usage patterns and outcomes (safety and effectiveness) of immunotherapy and/or TKI, for metastatic renal cell carcinoma in real-life practice	Immunotherapy and/or TKI

Primary Outcomes

Name	Time Points	Measure
To describe the efficacy of immunotherapy and/or TKI alone for the treatment of metastatic renal cell carcinoma in terms of progression-free survival (PFS) and overall survival (OS)	one and three years	Progression-free survival and duration of overall survival
Assess the potency of the sequence therapy in terms of first, second, and third line therapy with the current real-world clinical practice	one and three years	Overall response rate, time to response and tumor assessment



Key Secondary Outcomes

Name	Time Points	Measure
To describe the safety and toxicity profile of immunotherapy and/or TKI for fatigue, rash, nausea, pruritus and diarrhea and organ toxicity as liver, lungs, kidneys, thyroid and neurologic	one, three, six, twelve, and 36 months post treatment, and at 1st relapse	Lab data, ECG, Adverse events and serious adverse events
To compare patients' profile if the therapy is administered as first, second, or third line treatment options at one, three, six, twelve, and 36 months post treatment, and at 1st relapse	one, three, six, twelve, and 36 months post treatment, and at 1st relapse	Serious Adverse Events as pruritus, diarrhea and organ toxicity as liver, lungs, kidneys, thyroid and neurologic examination

Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files